Phio (PHIO) CEO Robert J. Bitterman Buys 2,000 Shares

What Happened
Robert J. Bitterman, Phio Pharmaceuticals' Chairman, President & CEO (and a director), reported an open-market purchase of 2,000 shares of PHIO common stock on 2026-09-22 at $1.03 per share, for a total reported cost of $2,058. This was a purchase (reporting code P), which is generally considered more informative to investors than routine sales.

Key Details

• Transaction date: 2026-09-22; filing date: 2026-09-23 (filed the next day).
• Price and amount: 2,000 shares at $1.03 per share; total value $2,058.
• Transaction code: P (purchase), reported as an open-market purchase.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — ownership totals include shares underlying unvested restricted stock units (RSUs).
• No 10b5-1 plan, tax-withholding, gift, or option-exercise details were reported in the excerpt.

Context
Purchases by executives can be viewed as a positive signal because they increase insider exposure to company stock, though this single, small-dollar purchase should be considered in the broader context of other insider activity and company fundamentals. The footnote indicates some reported ownership counts include unvested RSUs, which affects how much of the insider's stake is currently transferable.